Page not found

Search results

  1. Vanderbilt biochemists reveal the cause of Charcot-Marie-Tooth disease

    ... a protein that snakes through the lipid bilayer of the cell several times until it reaches the cell surface. Under disease conditions, ... in the Carter Lab, translating our data and model cell line work to nervous system cells.”  The work was supported by NIH ...

    sommers - 10/30/2020 - 12:43pm

  2. Partnership to help bring Zika virus therapy to clinic

    ... announced that it has signed a license agreement to use a cell line expression system developed by Horizon Discovery, a life sciences company ...

    sommers - 09/20/2019 - 2:07pm

  3. La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

    ... collaboration is to research and develop small-molecule BMP type-I receptor inhibitors designed to aid in treatment of rare genetic ... from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla’s proprietary ...

    steelmk - 10/02/2015 - 10:45am

  4. Researchers developing potential Coronavirus antibody therapies

    ... Crowe said. “Our partners have the manufacturing and product development expertise to turn these antibodies into effective ... company, has partnered with the VVC to develop custom cell-type specific isolation reagents to allow rapid and efficacious isolation of ...

    sommers - 03/26/2020 - 1:36pm

  5. Targeting diabetic kidney disease

    ... factor receptor (EGFR) is activated in mouse models of type 1 diabetes, and that drugs which inhibit EGFR prevent the development of ... the docking sites for a variety of molecules that regulate cell proliferation, maturation and cell death. Now in a study published ...

    sommers - 02/21/2019 - 9:51am

  6. VUMC scientists ‘sprint’ to find anti-Zika antibodies

    ... delivering it through a quick, intramuscular injection. Any cell that takes up the RNA will begin to produce the desired antibody almost ... PhD. They produce and optimize the RNA-encoded delivery product. Follow-up in-vivo evaluations of the RNA-delivered antibodies ...

    sommers - 02/21/2019 - 9:51am

  7. Tech Connect, Vol. 6, Issue 21: Current cancer drug discovery method flawed says VUMC study

    ... developed a new metric to evaluate a compound’s effect on cell proliferation — called the DIP (drug-induced proliferation) rate — ... outside inventor of a medical device, to evaluate potential product development collaboration with VUMC clinicians. ...

    steelmk - 11/10/2016 - 7:45am

  8. Tech Connect, Vol. 7, Issue 3: CTTC launches Startup Vanderbilt's Pre-Flight Program

    ... and technology development company for the Biohybrid solar cell technology invented by David Cliffel of the Department of Chemistry and ... medical device start-up company to discuss potential product development collaboration with Vanderbilt through a NIH Small Business ...

    steelmk - 11/10/2016 - 7:45am

  9. Tech Connect, Vol. 6, Issue 22: CTTC team presents, participates at 2016 SEMDA meeting

    ... resources on costly clinical trials.  Instead of measuring cell death at an arbitrary timepoint, one can capture the rate of cell death, ... the growth characteristics of each individual cancer cell line, and the speed at which the drug start working. ...

    steelmk - 11/10/2016 - 7:45am

  10. Announcing the creation of the Greater Nashville Venture Capital Association

    ... in various area of early stage investing, finance, product development, recruiting and other relevant topics to aspiring ...

    cttc_admin - 01/03/2024 - 2:44pm